Is Compliance More Complex with Digital Lab Management Systems?
10 min read
Ask a QA manager whether compliance gets harder when a lab goes digital and you will usually get a pause, then a qualified yes. The instinct is understandable. Paper is familiar. A signed binder feels controllable in a way that a cloud platform does not.
The honest answer is more interesting than YES or NO. Digital systems do not add new compliance obligations. GxP asked for the same things in 1995 that it asks for now. What changes is where the effort sits. On paper, compliance is a continuous human cost, paid in handwriting, initials, cross references and manual review, every day, by everyone. In a validated digital system, much of that daily cost disappears into the software, and a new cost appears in its place: configuration, validation and change control.
So compliance does not become more complex. It becomes concentrated. The daily work gets easier and the governance work gets more demanding. Labs that understand that trade early tend to have smooth transitions. Labs that assume buying compliant software is the transition tend to stall.
This article covers what GxP actually requires, why the digital version of it feels harder, and how to plan a transition that holds up under inspection.
Contents
The FIVE things every GxP framework is really asking for
If you work in a regulated laboratory, terms like GxP, GLP, GMP, ALCOA+, Annex 11 and 21 CFR Part 11 have already crossed your path, probably in a document you had to sign. It is worth stepping back from the acronyms to what they are actually asking for.
GxP stands for Good ”x” Practice, where the x changes with the area being regulated. It is an umbrella term for the regulations that ensure life science products are safe, consistent and of reliable quality. The three most common frameworks are GMP for manufacturing and product quality, GLP for non-clinical safety and toxicology studies, and GCP for clinical trials in human subjects.
GLP and GMP are the pair most often confused, and the distinction is worth getting right because it determines what an inspector will look for. GLP governs non clinical laboratory work such as toxicology, safety and preclinical studies, and its purpose is to make studies reproducible, traceable and scientifically defensible. GMP governs manufacturing and product quality, covering process validation, batch records, quality control and equipment qualification, and its purpose is to ensure products are made consistently to defined standards. Different operational areas, substantial overlap, one shared goal: trustworthy data, controlled processes, and work that is properly documented.
Strip away the framework specific language and five expectations remain constant, whichever letter the ”x” happens to be.
1. Data Integrity
At the center of every GxP framework is data you can trust. Regulators expect records to be accurate, complete, consistent, traceable and protected against unauthorised change.
This is where the ALCOA+ principles live: attributable, legible, contemporaneous, original and accurate, plus complete, consistent, enduring and available. Nine words that are easy to recite and harder to evidence.
The practical test is blunt. If a result can be modified without a trace, or nobody can determine who approved a record, the integrity of the entire process around it becomes questionable. Not just that record. The process.
2. Traceability and Auditability
Every regulated process must be reproducible, whether it is a toxicology study under GLP or a manufacturing batch under GMP. That requires a clear history of who performed an action, when it happened, what changed, why it changed, and who reviewed or approved it.
This is why audit trails, electronic signatures and version histories moved from nice to have to non negotiable. The critical word is contemporaneous. A history assembled after the fact from memory and loose notes is not a history. It is a reconstruction, and inspectors treat it as one.
3. Process Control
The essence of compliance is that processes are followed consistently, by everyone, every time. In practice that means controlled SOPs, defined workflows, change management, permissions that match roles, training procedures and controlled approvals.
Standardisation is not bureaucracy here. It is the mechanism that makes two results comparable, and the more standardised and controlled a process is, the lower the compliance risk attached to it.
4. Validation and Qualification
Validation remains the most demanding pillar. Regulators expect documented evidence that systems perform as intended within your specific environment and your specific workflows. That applies to ELNs, LIMS platforms, manufacturing systems, cloud infrastructure and instrument integrations alike.
GAMP 5 is the framework most regulated labs use to get there, applying a risk based approach across the full system lifecycle. When a lab implements an ELN, GAMP 5 helps answer five questions:
- How critical is this system to product quality or data integrity?
- Which functions carry the highest compliance risk?
- What level of validation documentation is appropriate?
- What testing is required before the system goes live?
- How will updates, changes and releases be managed over time?
The vendor has a real role in answering those questions, and a good one will supply validation documentation, testing evidence, infrastructure qualification support, security documentation and a defined release management process. What the vendor cannot do is validate the system for your intended use, your workflows, your SOPs and your quality environment. That responsibility does not transfer, and no contract can move it.
5. People
Trained, qualified people, with training records that prove it, plus continued professional development and change management when roles or processes shift.
This is the pillar most often left out of software conversations and the one inspectors reach for first when records look inconsistent. A perfectly validated system operated by untrained users is still a finding.
Everything else in a GxP discussion is a variation on those five.
Two regulations, one expectation
The two documents that govern computerised systems are FDA 21 CFR Part 11 in the US and EU GMP Annex 11 in Europe. They read differently. Part 11 is written around electronic records and electronic signatures. Annex 11 is written around computerised systems and risk based validation. Compare their substance and they converge almost completely: data integrity, security and access control, audit trails, and evidence that the system is under control.
For a lab operating in both markets, that convergence is good news. You are not building two compliance programmes. You are building one, documented in a way that satisfies both readings.
What changed recently, and why it matters now
Two developments are worth knowing about, because they shape what auditors will ask for over the next few years.
Annex 11 is being rewritten for the first time since 2011. The European Commission and PIC/S published the draft revision on 7 July 2025, alongside a new Annex 22 on artificial intelligence and a revised Chapter 4 on documentation. Public consultation closed on 7 October 2025 and final publication is expected in mid 2026. The draft expands the annex from five pages to nineteen, organised into seventeen chapters, and adds or significantly expands supplier and service management, audit trail expectations, periodic reviews, and a substantial security chapter covering areas such as patching, penetration testing and access control. The Commission describes the revised annex as strengthening lifecycle management of computerised systems, applying quality risk management principles throughout, and reinforcing obligations around supplier oversight.
Read that list again and notice what it is really about. Cybersecurity and vendor oversight are becoming explicit GMP topics. Your software supplier’s security posture stops being an IT procurement question and becomes part of your compliance file.
The FDA has formalised a lighter approach to validation. On 24 September 2025 the FDA issued its final guidance on Computer Software Assurance for Production and Quality System Software, following the 2022 draft. It superseded Section 6 of the older General Principles of Software Validation and confirmed the risk based, least burdensome approach to software assurance. The reframing is simple: define the intended use, evaluate whether the output affects quality, and scale the assurance effort to the risk, rather than applying uniform scripted testing to everything.
The direction of travel is consistent on both sides of the Atlantic. Regulators want proportionate validation effort concentrated where the risk actually is, and they want to see the thinking that got you there.
The complexity does not disappear, it relocates
Here is the part that rarely makes it into vendor material.
Paper hides its own cost
A paper process looks simple because its compliance cost is distributed and invisible. Nobody itemises the time spent initialling corrections, chasing signatures, cross referencing a batch record to a calibration certificate, or reconstructing what happened three months ago from four different binders. It is absorbed as normal work.
Paper also has one genuine advantage worth acknowledging. You control the whole process. No supplier changes it underneath you. The cost of that control is that improvement stops. The status quo becomes comfortable and nothing gets better.
Software makes its cost visible and moves it upstream
Three shifts explain why a digital transition feels harder than it is.
A human habit becomes a system configuration. On paper, “only the study director signs off” is a practice people follow. In software it is a permission scheme somebody has to design, document, test and maintain. That is more visible work, and it is also stronger control. But it has to be done deliberately, once, before go live.
Your change control now extends to somebody else’s release cycle. This is the real difference. A small software change can ripple into a validated process. If your supplier ships continuously with little warning, your validated state is under constant, unpredictable pressure. Release cadence and advance notice are compliance features, not commercial details.
Audit trails make inconsistency visible. A complete audit trail is what regulators want, and it also removes any place to hide. Inspectors increasingly review the trail itself, not just the final record. This is not a reason to avoid audit trails. It is a reason to align practice with procedure before the system starts recording the gap.
The misconception that costs the most time
No electronic lab notebook or lab management system is GxP compliant on its own. Software cannot be compliant. Only an organisation can be, in the way it uses software.
This is the shared responsibility model, and GAMP 5 names it precisely. A configurable platform like an ELN is a Category 4 system, which means it is validated jointly: the supplier evidences the quality of the product, the regulated organisation evidences the intended use. Neither half is sufficient alone, and the boundary between them is exactly where transition projects go wrong.
Software can deliver audit trails, electronic signatures, version control, role based access, secure storage and traceability. Your organisation still owns SOPs, training, validation, QA oversight, change control and risk management. Compliance originates from people, processes and governance. Software makes it easier to achieve, easier to prove, and easier to sustain over time.
Planning a transition that holds up
A paper to digital move in a regulated lab is a validated change. It deserves the same rigour as any other quality critical change. Six moves account for most of the difference between projects that land and projects that drag.
Six questions worth asking any vendor
- What validation documentation do you provide with each release, and how far in advance?
- How many releases per year, and can we defer or schedule our upgrade?
- Do we get a separate validation environment alongside production?
- Can audit trails be edited or deleted by anyone, including your staff or ours?
- Which security and quality certifications do you hold, and can we see the current reports?
- Where is our data hosted, and what are the options if our contract requires otherwise?
The answers tell you more about your future compliance workload than any feature list.
How SciNote supports each pillar for regulated laboratories
SciNote is used by pharmaceutical and biotechnology companies, CROs, CDMOs, medical device manufacturers, clinical and diagnostic laboratories, quality control environments, and government and academic research labs. Some of those teams work under full GxP controls, some do not, and many do both in the same organisation.
Taking the pillars in the same order, here is what the platform contributes and what it leaves with you.
On the Platinum plan the release model is built around validation workload rather than against it. Two scheduled production updates a year, at the end of Q1 and Q3. Feature scope locked two to three months ahead, and every feature runs in the standard platform for at least two months before it reaches a validated system. Three environments: a sandbox that tracks agile releases, a dedicated validation environment updated four to six weeks before production, and production itself. Validation notice arrives eight to ten weeks before the update with release notes, OQ templates, URS and confirmed dates, and an IQ report confirming successful deployment lands on release day. Even a rare off cycle hotfix gets a cross functional risk assessment and fresh IQ and OQ reports. For teams that want hands on help, our quality assurance services can prepare customer specific URS, IQ and OQ documents, configure your environments and execute functional testing alongside your QA team.
Two further areas cut across all five pillars rather than sitting inside any one of them.
Part 11 and Annex 11 functionality. Time stamped electronic signatures linked to electronic records, strict access control with SSO or unique credentials, two factor authentication, configurable session timeout, password rules, IP restrictions, encryption, multiple daily backups, business continuity and disaster recovery, and a choice of geographical data residence including on premise.
Underlying quality and security. A QMS that includes the software development lifecycle, internal verification and risk assessment processes, ISO 27001 certification, SOC 2 Type I and Type II, Cyber Essentials, and quality agreements where required. Current reports are available in the SciNote Trust Center.
And to be equally clear about the other half. Performance qualification against your workflows, your own customer specific URS, SOPs for system use, access management, change control and archiving, user training with documented records, and internal risk assessments with periodic review and requalification all stay with your team. Any vendor claiming otherwise is describing something that does not exist.
Seven features cover most regulated use cases
A pillar stays abstract until you map it onto work. Below are the regulated activities a lab actually has to stand behind, grouped into four families, with what each one has to prove and the features that carry it. The feature set is smaller than most evaluations assume. Seven capabilities do nearly all of the work: controlled protocol and results templates, inventory, audit trail, electronic signatures, role based access, report generation, and workspace level configuration.
Structured protocol execution
Process development and technology transfer, analytical method validation, stability studies, cleaning validation, verification and validation studies, equipment qualification, and CSV or OQ test script execution. What has to be provable is that the method was executed as written, that acceptance criteria were defined in advance rather than after seeing the data, and that any deviation is visible. Controlled templates with locked steps do most of the work here, because a free form note cannot demonstrate a predefined criterion. ICH Q2(R1) method validation is the clearest example, and for medical device teams the same methodology applies under 21 CFR Part 820.
Instrument and equipment management
Calibration and preventive maintenance. What has to be provable is that the instrument was inside its calibration window at the moment it was used, not merely that a certificate exists somewhere. An out of calibration instrument can invalidate every result from that period, and undocumented maintenance counts as no maintenance at all. This is where snapshots of calibration and maintenance status at the time of use matter more than any dashboard.
Inventory, sample and materials management
Sample chain of custody, reagent and consumable traceability by lot, supplier and expiry, reference standard and critical reagent control, cell line and biological material tracking, incoming material inspection and release, batch documentation at lab scale, and certificate of analysis generation. What has to be provable is where something came from, where it went, and that it was fit to use when it was used. If a lot is later implicated in a quality event, every affected study has to be identifiable quickly. A CoA generated directly from the test records is credible in a way that one typed up afterwards is not.
Parallel GxP and non GxP environments
What has to be provable is that regulated and unregulated work never mixed. Siloed workspaces with their own access, their own audit trail and no data crossover let R&D stay fast while the regulated side holds up, which is the practical answer to the over control problem described earlier.
The useful conclusion for anyone evaluating systems: the question is not whether a platform lists these seven capabilities, because most will. It is whether each one can be enforced at the level your process actually needs, and whether the resulting record can be exported in a human readable form that survives without the software.
So, is it more complex?
Compliance is not more complex in a digital laboratory. It is differently distributed. Less effort in the moment of recording, more effort in the design, validation and governance of the system doing the recording. Most labs find that trade strongly favourable, because the upfront work is finite and repeatable while the paper cost is permanent.
What has not changed is the substance. GxP has always been about building processes and systems that regulators, organisations and scientists can trust. Software does not replace that. It gives you a far better way to prove it.
Download SciNote Platinum Plan Overview:
If you are assessing vendors for a GMP, GLP or GCP environment, it answers the questions your quality unit will ask before procurement gets involved.
